Acute cholangitis occurred in 3 patients from Group A and in 14 patients from Group B (P=0.03). Mortality related to cholangitis occurred in one patient from Group A and three patients from Group B (P=n.s.). The mean follow-up was 13.5 months (range 2-23). Stone clearance after long term stenting occurred in 24 patients from Group A (61.5%) and in 21 patients from group B (53.8%) (P=n.s.).\n\nConclusions: In patients with bile duct stones who were treated with biliary plastic stents, the best stent management to avoid cholangitis was stent changing at defined intervals (every 3 months in the current study). The data

confirmed that plastic biliary stenting may decrease stone size with a high percentage of subsequent total stone clearance.”
“Objectives This study sought to assess the effect of short-term apolipoprotein (apo) A-I-Milano administration on plaque size and on suspected markers of plaque vulnerability.\n\nBackground JQ1 clinical trial Long-term lipid-lowering interventions can regress and stabilize atherosclerotic plaques. However, the majority of recurrent events occur early after the first episode. Interventions able to acutely induce plaque regression and stabilization are lacking. Regression of human

coronary lesions after 5 weeks of treatment with apoA-I-Milano administration has been shown. However, there are no data regarding its effect on plaque vulnerability.\n\nMethods IWR-1-endo ic95 Advanced aortic lesions were induced in New Zealand White rabbits (n = 40). Plaque size was assessed by magnetic resonance imaging

(MRI) at the end of atherosclerosis induction. Animals were randomized to placebo or apoA-I-Milano phospholipids (ETC-216), 2 infusions 4 days apart. After the last dose, another MRI study was performed and aortas were processed for cellular composition and gene protein expression of markers associated with plaque instability.\n\nResults Pre-treatment MRI showed Smad inhibitor similar plaque size in both groups, whereas post-treatment MRI showed 6% smaller plaques in apoA-I-Milano-treated animals compared with placebo (p = 0.026). The apoA-I-Milano treatment induced a 5% plaque regression (p = 0.003 vs. pre-treatment), whereas the placebo showed no significant effect. Plaque regression by apoA-I-Milano was associated with a reduction in plaque macrophage density and a significant down-regulation in gene and protein expression of tissue factor, monocyte chemoattractant protein-1, and cyclooxygenase-2, as well as marked decrease in gelatinolytic activity. Conversely, cyclooxygenase-1 was significantly up-regulated.\n\nConclusions Acute plaque regression observed after short-term apoA-I-Milano administration was associated with a significant reduction in suspected makers of plaque vulnerability in an experimental model of atherosclerosis.”
“Purpose: To investigate the use of a software-based pre-treatment QA system for VMAT, which incorporates realistic linac motion during delivery.